JP2020534017A5 - - Google Patents

Download PDF

Info

Publication number
JP2020534017A5
JP2020534017A5 JP2020516818A JP2020516818A JP2020534017A5 JP 2020534017 A5 JP2020534017 A5 JP 2020534017A5 JP 2020516818 A JP2020516818 A JP 2020516818A JP 2020516818 A JP2020516818 A JP 2020516818A JP 2020534017 A5 JP2020534017 A5 JP 2020534017A5
Authority
JP
Japan
Prior art keywords
seq
antibody
composition
antigen
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020516818A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020534017A (ja
JP7303802B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/052253 external-priority patent/WO2019060750A2/en
Publication of JP2020534017A publication Critical patent/JP2020534017A/ja
Publication of JP2020534017A5 publication Critical patent/JP2020534017A5/ja
Priority to JP2023103361A priority Critical patent/JP2023138957A/ja
Application granted granted Critical
Publication of JP7303802B2 publication Critical patent/JP7303802B2/ja
Priority to JP2024215117A priority patent/JP2025061650A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020516818A 2017-09-23 2018-09-21 A33抗体組成物および放射性免疫療法におけるその使用方法 Active JP7303802B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023103361A JP2023138957A (ja) 2017-09-23 2023-06-23 A33抗体組成物および放射性免疫療法におけるその使用方法
JP2024215117A JP2025061650A (ja) 2017-09-23 2024-12-10 A33抗体組成物および放射性免疫療法におけるその使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762562373P 2017-09-23 2017-09-23
US201762562374P 2017-09-23 2017-09-23
US62/562,373 2017-09-23
US62/562,374 2017-09-23
PCT/US2018/052253 WO2019060750A2 (en) 2017-09-23 2018-09-21 A33 ANTIBODY COMPOSITIONS AND METHODS OF USE IN RADIOIMMUNOTHERAPY

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023103361A Division JP2023138957A (ja) 2017-09-23 2023-06-23 A33抗体組成物および放射性免疫療法におけるその使用方法

Publications (3)

Publication Number Publication Date
JP2020534017A JP2020534017A (ja) 2020-11-26
JP2020534017A5 true JP2020534017A5 (https=) 2021-10-28
JP7303802B2 JP7303802B2 (ja) 2023-07-05

Family

ID=65810903

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020516818A Active JP7303802B2 (ja) 2017-09-23 2018-09-21 A33抗体組成物および放射性免疫療法におけるその使用方法
JP2023103361A Pending JP2023138957A (ja) 2017-09-23 2023-06-23 A33抗体組成物および放射性免疫療法におけるその使用方法
JP2024215117A Pending JP2025061650A (ja) 2017-09-23 2024-12-10 A33抗体組成物および放射性免疫療法におけるその使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023103361A Pending JP2023138957A (ja) 2017-09-23 2023-06-23 A33抗体組成物および放射性免疫療法におけるその使用方法
JP2024215117A Pending JP2025061650A (ja) 2017-09-23 2024-12-10 A33抗体組成物および放射性免疫療法におけるその使用方法

Country Status (9)

Country Link
US (2) US11555072B2 (https=)
EP (1) EP3684369A4 (https=)
JP (3) JP7303802B2 (https=)
KR (1) KR102783937B1 (https=)
CN (1) CN111372590A (https=)
AU (2) AU2018338322B2 (https=)
CA (1) CA3076611A1 (https=)
IL (1) IL273484B2 (https=)
WO (1) WO2019060750A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2904969C (en) 2013-03-13 2025-06-17 Imaginab, Inc. DIFFERENTIATION CLUSTER ANTIGEN-BINDING GENETIC CONSTRUCTIONS 8
WO2017027325A1 (en) 2015-08-07 2017-02-16 Imaginab, Inc. Antigen binding constructs to target molecules
US11122038B1 (en) * 2017-05-18 2021-09-14 United Services Automobile Association (Usaa) Methods and systems for authentication of new users
CN113614109A (zh) 2018-12-21 2021-11-05 Ose免疫疗法公司 双功能抗pd-1/il-7分子
EP4257199A3 (en) 2018-12-21 2024-01-10 Ose Immunotherapeutics Humanized anti-human-pd-1 antibody
BR112021012027A2 (pt) 2018-12-21 2021-11-03 Ose Immunotherapeutics Molécula bifuncional direcionada contra pd-1 humano
AU2019409805A1 (en) 2018-12-21 2021-07-22 Ose Immunotherapeutics Bifunctional anti-PD-1/SIRPA molecule
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
JP7730295B2 (ja) * 2019-04-08 2025-08-27 メモリアル スローン ケタリング キャンサー センター Cd19抗体およびこれを使用する方法
US20230365636A1 (en) 2020-11-16 2023-11-16 Technische Universität München Bioorthogonal reporter gene system
CN117794568A (zh) * 2020-11-18 2024-03-29 纪念斯隆凯特琳癌症中心 抗gpa33多特异性抗体和其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07504334A (ja) * 1992-12-10 1995-05-18 セルテック・リミテッド A33抗原に対するヒト化抗体
US6307026B1 (en) 1992-12-10 2001-10-23 Celltech Limited Humanized antibodies directed against A33 antigen
WO1998052976A1 (en) * 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
WO1999055369A1 (en) * 1998-04-28 1999-11-04 Smithkline Beecham Corporation Monoclonal antibodies with reduced immunogenicity
US7579187B2 (en) * 2004-09-06 2009-08-25 Kyoma Hakko Kirin Co., Ltd. Anti-A33 antibody
EP2840091A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
WO2016054005A1 (en) * 2014-09-30 2016-04-07 The Medical College Of Wisconsin, Inc. Universal platform for targeting therapies to treat neurological diseases
CA2976074A1 (en) * 2015-02-09 2016-08-18 Memorial Sloan Kettering Cancer Center Multi-specific antibodies with affinity for human a33 antigen and dota metal complex and uses thereof
RS61907B1 (sr) * 2015-04-06 2021-06-30 Subdomain Llc Polipeptidi koji sadrže de novo vezujući domen i njihova primena

Similar Documents

Publication Publication Date Title
JP2020534017A5 (https=)
ES3003809T3 (en) Chimeric antigen receptors specific for b-cell maturation antigen and encoding polynucleotides
IL273484B1 (en) A33 antibody compositions and methods of using the same in radioimmunotherapy
JP7573441B2 (ja) ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法
CN108124445B (zh) Ctla4抗体、其药物组合物及其用途
KR20230024984A (ko) Cd70-지시 암 면역요법용 유전적으로 변형된 자연 살해 세포
CN110214152B (zh) 模块化四聚体双特异性抗体平台
JP7450585B2 (ja) CD66cに特異的に結合する抗体およびその用途
JP2020523029A5 (https=)
KR102380150B1 (ko) Gitr 항체, 방법, 및 용도
ES3054945T3 (en) Antibodies for chelated radionuclides and clearing agents
JP2021517816A5 (https=)
CN117343193A (zh) 双特异性抗体及其制备和使用方法
EP4238990A1 (en) Fully human antibody targeting cd5, and fully human chimeric antigen receptor (car) and application thereof
CN117304325A (zh) B7h3抗体及其用途
CN118339187A (zh) 抗pd-1抗体及其用途
JP2022531229A (ja) 併用治療
JPWO2020210232A5 (https=)
US20260028402A1 (en) Anti-cd100 antibody and use thereof
JPWO2021046331A5 (https=)
JPWO2020264211A5 (https=)
CN114616245B (zh) 一种抗cd38的抗体及其用途
JPWO2022032004A5 (https=)
CA3107524C (en) Humanized Monocolonial Antibody Against CTLA4: Preparation Method and Application
KR20240127523A (ko) 항-cntn4 항체 및 그의 용도